CYP3A4 and COVID-19: Simnotrelvir/ritonavir was conditionally approved in January 2023 in China for the treatment of adult patients with mild-to-moderate COVID-19 (Cao et al., 2024).Ritonavir is a potent inhibitor of CYP3A4, while simnotrelvir is a substrate of CYP3A.